Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Omeros Corporation (NASDAQ:OMER) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $40.3333.

OMER has been the topic of a number of recent research reports. HC Wainwright raised their price target on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. Finally, Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th.

Insider Buying and Selling

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its holdings in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares during the period. State of Wyoming acquired a new stake in shares of Omeros during the 4th quarter worth approximately $25,000. AQR Capital Management LLC boosted its position in shares of Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,532 shares in the last quarter. ProShare Advisors LLC increased its stake in Omeros by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 1,637 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in Omeros by 6.1% in the fourth quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock valued at $523,000 after acquiring an additional 1,750 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Trading Up 1.2%

NASDAQ:OMER opened at $11.27 on Wednesday. The stock has a 50 day simple moving average of $11.85 and a 200 day simple moving average of $9.32. The stock has a market cap of $799.04 million, a P/E ratio of -5.58 and a beta of 2.45. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.